| Active Not Recruiting | Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory NCT04756401 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple NCT05363111 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma NCT05391750 | Emory University | Phase 1 |
| Active Not Recruiting | Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple M NCT05514990 | University of Southern California | Phase 1 / Phase 2 |
| Recruiting | Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With NCT05312255 | Roswell Park Cancer Institute | N/A |
| Active Not Recruiting | Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refracto NCT05411497 | Mayo Clinic | Phase 1 |
| Terminated | Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug ( NCT05288062 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma NCT04850599 | OHSU Knight Cancer Institute | Phase 2 |
| Terminated | Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies NCT05191472 | Alfred Chung, MD | Phase 2 |
| Terminated | Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refra NCT04956302 | Abdullah Khan | Phase 1 |
| Active Not Recruiting | Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Car NCT04090619 | M.D. Anderson Cancer Center | — |
| Terminated | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously U NCT04892264 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neop NCT04640779 | Mayo Clinic | Phase 1 |
| Terminated | Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma NCT04205240 | Srinivas Devarakonda | Phase 2 |
| Terminated | Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple My NCT04407442 | University of California, San Francisco | Phase 2 |
| Recruiting | Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma NCT04508790 | City of Hope Medical Center | Phase 2 |
| Withdrawn | Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma NCT03841565 | Academic and Community Cancer Research United | Phase 2 |
| Active Not Recruiting | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in P NCT04205409 | University of Washington | Phase 2 |
| Completed | Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy NCT04409314 | University of California, San Francisco | — |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Withdrawn | Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refra NCT03856112 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multipl NCT03710421 | City of Hope Medical Center | Phase 1 |
| Completed | Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma NCT03829020 | Mayo Clinic | Phase 1 |
| Terminated | Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant NCT03622775 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Re NCT03701321 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Pa NCT03763162 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma NCT03605719 | Emory University | Phase 1 |
| Terminated | Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemoth NCT03457142 | Roswell Park Cancer Institute | Phase 2 |
| Withdrawn | Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant NCT03328936 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Withdrawn | TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Re NCT03506802 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma NCT03506360 | Mayo Clinic | Phase 2 |
| Completed | Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma NCT03267888 | Emory University | Phase 1 / Phase 2 |
| Terminated | BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent NCT03502577 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma NCT03399539 | Mayo Clinic | Phase 1 |
| Terminated | Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis NCT03303950 | University of Utah | Phase 2 |
| Terminated | Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT03333746 | Yvonne Efebera | Phase 2 |
| Completed | Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myelom NCT03311828 | City of Hope Medical Center | Phase 1 |
| Terminated | Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma NCT03256045 | University of Washington | Phase 2 |
| Completed | Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple My NCT03338972 | Fred Hutchinson Cancer Center | Phase 1 |
| Terminated | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelate NCT03246906 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chr NCT02948283 | City of Hope Medical Center | Phase 1 |
| Completed | Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multipl NCT03202628 | Mayo Clinic | Phase 2 |
| Completed | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in P NCT03128359 | City of Hope Medical Center | Phase 2 |
| Recruiting | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemi NCT03017820 | Mayo Clinic | Phase 1 |
| Withdrawn | Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma NCT02971410 | Wake Forest University Health Sciences | EARLY_Phase 1 |
| Terminated | Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplan NCT03015792 | Mayo Clinic | Phase 1 |
| Completed | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT02960646 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangemen NCT02765854 | Emory University | Phase 2 |
| Active Not Recruiting | Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer U NCT02861417 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma NCT02569320 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Completed | Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multip NCT02697344 | Mayo Clinic | Phase 1 |
| Completed | Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma NCT02633059 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT02509052 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis NCT02593123 | Virginia Commonwealth University | Phase 2 |
| Completed | Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patie NCT02506959 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple My NCT02514382 | University of Southern California | Phase 1 |
| Completed | Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Tr NCT02504359 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multipl NCT02119468 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Mu NCT02095834 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Mye NCT01946152 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myelo NCT01794039 | Mayo Clinic | Phase 2 |
| Completed | Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma NCT02086552 | Mayo Clinic | Phase 2 |
| Completed | SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple M NCT01955434 | Mayo Clinic | Phase 2 |
| Completed | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT01989598 | National Cancer Institute (NCI) | Phase 2 |
| Completed | S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma NCT01903811 | SWOG Cancer Research Network | Phase 2 |
| Completed | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Tran NCT01822509 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma NCT01711528 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell NCT01527045 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refra NCT01689987 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leu NCT01372540 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib NCT01415882 | Mayo Clinic | Phase 2 |
| Completed | Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma NCT01301807 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Don NCT01163357 | City of Hope Medical Center | Phase 1 |
| Completed | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated NCT01231412 | Fred Hutchinson Cancer Center | Phase 3 |
| Terminated | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01028716 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients NCT01008462 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma NCT01085214 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma NCT02353572 | University of Colorado, Denver | Phase 1 / Phase 2 |
| Completed | Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myel NCT00966693 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by NCT00789776 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple My NCT00450814 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor He NCT00068718 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |